Skip to main content
Clinical Trials/NCT02918630
NCT02918630
Completed
Not Applicable

E-cigarettes to Promote Smoking Reduction Among Individuals With Schizophrenia

The University of Texas Health Science Center, Houston1 site in 1 country7 target enrollmentOctober 2016

Overview

Phase
Not Applicable
Intervention
Nicotine Patch
Conditions
Tobacco Smoking
Sponsor
The University of Texas Health Science Center, Houston
Enrollment
7
Locations
1
Primary Endpoint
Change in Smoking as Assessed by Urinary Cotinine Levels
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this study is to assess if access to an electronic nicotine delivery device, or e-cigarette, in addition to nicotine patch (21 mg) can help reduce cigarette smoking among individuals diagnosed with schizophrenia compared to nicotine patch alone.

Registry
clinicaltrials.gov
Start Date
October 2016
End Date
August 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jin Ho Yoon

Assistant Professor

The University of Texas Health Science Center, Houston

Eligibility Criteria

Inclusion Criteria

  • Be diagnosed with schizophrenia
  • Be in stable medical condition (DSM-V)
  • report smoking ≥10 tobacco cigarettes/day
  • present a breath CO ≥10 ppm
  • report wanting to reduce their cigarette smoking
  • be fluent in English
  • have a stable living situation

Exclusion Criteria

  • be currently pregnant or breastfeeding
  • report wanting to quit smoking in the immediate future
  • test positive for illicit drugs except THC
  • have any illness, medical condition, or use of medications, which in the opinion of the study physicians would preclude safe and/or successful completion of the study

Arms & Interventions

Nicotine Replacement Therapy - Nicotine Patch

Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.

Intervention: Nicotine Patch

Nicotine Replacement Therapy + E-cigarette

The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).

Intervention: Nicotine Patch

Nicotine Replacement Therapy + E-cigarette

The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).

Intervention: E-cigarette

Outcomes

Primary Outcomes

Change in Smoking as Assessed by Urinary Cotinine Levels

Time Frame: Baseline, Week 5

Number of Cigarettes Smoked Per Day as Assessed by Self-report Via Timeline Follow-back

Time Frame: week 5

Timeline follow-back involves asking participants to retrospectively estimate their cigarette use in the week prior to the interview date. An average number of cigarettes per day was calculated for each participant, and the average of the average number of cigarettes per day for all participants is reported below.

Change in Smoking as Assessed by Breath Carbon Monoxide Levels

Time Frame: Baseline, Week 5

Secondary Outcomes

  • Feasibility as Assessed by Percent of Participants Who Completed the Study(week 5)

Study Sites (1)

Loading locations...

Similar Trials